Lazard Asset Management
LEGN icon

Lazard Asset Management’s Legend Biotech LEGN Stock Holding History

Lazard Asset Management’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-9
Closed – – 2445
2024
Q4 		$0 Hold
9
– – ﹤0.01% 2419
2024
Q3 		$0 Sell
9
-16
-64% -$852 ﹤0.01% 2373
2024
Q2 		$0 Sell
25
-355
-93% -$16.4K ﹤0.01% 2345
2024
Q1 		$20K Sell
380
-210
-36% -$12.7K ﹤0.01% 1841
2023
Q4 		$34K Buy
590
+21
+4% +$1.33K ﹤0.01% 1993
2023
Q3 		$37K Buy
569
+25
+5% +$1.74K ﹤0.01% 1941
2023
Q2 		$36K Buy
544
+18
+3% +$1.18K ﹤0.01% 1932
2023
Q1 		$24K Sell
526
-163
-24% -$7.97K ﹤0.01% 2016
2022
Q4 		$33K Buy
+689
New +$33.4K ﹤0.01% 1982

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Lazard Asset Management's LEGN Position: Q1 2025 in Review

Lazard Asset Management sold out of Legend Biotech (LEGN) in Q1 2025, closing a stake of 9 shares.

Lazard Asset Management first reported a position in LEGN in Q4 2022 and held it in 9 quarters. The position peaked at $37K in Q3 2023. 208 funds tracked by Wall St. Rank hold LEGN as of Q1 2025.

  • Lazard Asset Management reported no remaining Legend Biotech position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 9 Legend Biotech shares in Q1 2025.
  • Lazard Asset Management first reported a position in Legend Biotech in Q4 2022 and held it in 9 quarters.
  • Lazard Asset Management's Legend Biotech position peaked at $37K in Q3 2023.
  • 208 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.